Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$155.90 +0.2%	$153.63	$140.68 ▼ $169.99	$374.29B	0.41	8.05 million shs	3.48 million shs
MRK Merck & Co., Inc.	$80.97 -1.7%	$79.22	$73.31 ▼ $129.93	$206.88B	0.39	13.26 million shs	7.73 million shs
NVS Novartis	$121.90 -1.5%	$114.67	$96.06 ▼ $124.45	$261.54B	0.59	1.59 million shs	955,240 shs
PFE Pfizer	$25.45 +0.5%	$23.62	$20.92 ▼ $31.54	$143.95B	0.58	41.63 million shs	27.10 million shs
RHHBY Roche	$40.44 -1.7%	$40.08	$33.76 ▼ $44.31	$262.45B	0.45	1.24 million shs	624,514 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.14%	+2.14%	+0.14%	-2.69%	+6.55%
MRK Merck & Co., Inc.	+0.75%	+3.29%	+8.05%	-4.59%	-35.52%
NVS Novartis	+0.63%	+5.00%	+6.12%	+10.20%	+16.31%
PFE Pfizer	+1.16%	+4.24%	+8.00%	+4.22%	-9.02%
RHHBY Roche	0.00%	+2.13%	+1.16%	+2.82%	+19.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JNJ Johnson & Johnson	4.8489 of 5 stars	2.3	5.0	4.2	3.9	3.1	1.7	1.9
MRK Merck & Co., Inc.	4.9956 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVS Novartis	1.2087 of 5 stars	1.0	3.0	2.5	0.0	2.2	0.0	1.3
PFE Pfizer	4.8475 of 5 stars	2.3	3.0	4.2	4.3	2.2	1.7	3.1
RHHBY Roche	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	9.61% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	34.85% Upside
NVS Novartis	2.00	Hold	$123.67	1.45% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside
RHHBY Roche	2.57	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest JNJ, RHHBY, MRK, PFE, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
4/30/2025	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform	$22.00 ➝ $23.00
4/30/2025	PFE Pfizer	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$29.00 ➝ $27.00
4/30/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$88.82B	4.22	$13.15 per share	11.86	$29.69 per share	5.25
MRK Merck & Co., Inc.	$64.17B	3.17	$9.31 per share	8.70	$18.33 per share	4.42
NVS Novartis	$50.32B	5.12	$10.54 per share	11.57	$21.59 per share	5.65
PFE Pfizer	$63.63B	2.27	$4.39 per share	5.80	$15.62 per share	1.63
RHHBY Roche	$68.73B	3.75	$3.24 per share	12.48	$6.44 per share	6.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$14.07B	$8.99	17.34	14.08	2.35	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.79	8.18	0.85	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.05	13.84	1.70	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
RHHBY Roche	$9.40B	N/A	0.00	13.48	3.16	N/A	N/A	N/A	7/24/2025 (Estimated)

Latest JNJ, RHHBY, MRK, PFE, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	3.34%	N/A	57.84%	64 Years
MRK Merck & Co., Inc.	$3.24	4.00%	N/A	47.16%	14 Years
NVS Novartis	$2.60	2.13%	N/A	40.63%	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years
RHHBY Roche	$0.87	2.15%	N/A	N/A	N/A

Latest JNJ, RHHBY, MRK, PFE, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.49	1.26	1.03
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96
RHHBY Roche	0.85	1.48	1.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%
PFE Pfizer	68.36%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.13%
NVS Novartis	0.01%
PFE Pfizer	0.06%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
RHHBY Roche	103,249	6.38 billion	N/A	Not Optionable

JNJ, RHHBY, MRK, PFE, and NVS Headlines

Recent News About These Companies

Changes to the Roche Enlarged Corporate Executive Committee

June 30 at 2:00 AM | globenewswire.com

RHHBY - Roche Holding AG ADR Trailing Returns - Morningstar

June 27, 2025 | morningstar.comM

RHHBY Roche Holding AG - Seeking Alpha

June 27, 2025 | seekingalpha.com

RHHBY - Roche Holding AG ADR Key Metrics - Morningstar

June 25, 2025 | morningstar.comM

RHHBY - Roche Holding AG ADR Dividends - Morningstar

June 24, 2025 | morningstar.comM

Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript

June 23, 2025 | seekingalpha.com

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

June 23, 2025 | uk.finance.yahoo.com

Altrius Capital Management Inc Acquires 6,545 Shares of Roche Holding AG (OTCMKTS:RHHBY)

June 22, 2025 | marketbeat.com

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | uk.finance.yahoo.com

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | finance.yahoo.com

Roche's Genentech reports positive results from lymphoma trial

June 20, 2025 | msn.com

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | businesswire.com $https://www.businesswire.com/news/home/20250620976164/en/genentech%e2%80%99s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma/$

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/20/3102847/0/en/roche-s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma.html$

UBS Keeps Their Buy Rating on Roche Holding AG (RHHVF)

June 18, 2025 | theglobeandmail.com

Roche And Prothena: Why Moving On Makes Sense

June 18, 2025 | seekingalpha.com

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 17, 2025 | marketbeat.com

Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue

June 16, 2025 | seekingalpha.com

Sarepta crashes after second death linked to Roche-partnered Elevidys

June 16, 2025 | msn.com

Genentech Provides Update on Phase III Verona Study

June 16, 2025 | businesswire.com

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

June 16, 2025 | zacks.com

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

June 16, 2025 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ, RHHBY, MRK, PFE, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

$155.90 +0.34 (+0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$155.75 -0.15 (-0.10%)

As of 04:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$80.97 -1.42 (-1.72%)

Closing price 03:59 PM Eastern

Extended Trading

$80.99 +0.02 (+0.02%)

As of 04:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$121.90 -1.91 (-1.54%)

Closing price 03:30 PM Eastern

Extended Trading

$123.50 +1.60 (+1.32%)

As of 04:04 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche OTCMKTS:RHHBY

$40.44 -0.71 (-1.73%)

As of 01:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time